The PBMs say out-of-pocket insulin costs have fallen sharply since 2019. The Pharmaceutical Care Management Association, pharmacy benefit managers' trade group, says the Federal Trade Commission's attack on PBMs' role in negotiating insulin prices is the result of a biased, anti-industry investigation.

In a move to address escalating insulin prices, the Federal Trade Commission (FTC) has initiated action against the three largest prescription drug benefit managers (PBMs) in the

The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said Friday in announcing an administrative complaint against firms that are divisions of CVS Health,

Millions of Americans with diabetes need insulin to survive, yet for many of these vulnerable patients, their insulin drug costs have skyrocketed over the past decade thanks in part to powerful PBMs and their greed,

The Federal Trade Commission (FTC) has sued the top three pharmacy benefit managers (PBMs) in the US for operating a "perverse drug rebate system" that it claims artificially inflated the prices of insulin products.

The FTC said CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx profit at the expense of patients forced to pay more for insulin.

The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts.

The enforcement action is part of an escalating conflict between the FTC and the three pharmacy benefit managers that together control about 80% of prescriptions filled in the US.

Regulators say the nation's largest pharmacy benefit managers are partly to blame for the soaring cost of insulin in the U.S.